Pompano Beach, FL, Nov. 01, 2017 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (the “Company”) announced today that, due to the Company’s acquisition and expansion activity over the past three years, it has completed and filed an “Issuer Company-Related Action Notification” with the Financial Industry Regulatory Authority (“FINRA”) requesting that the Company’s name be changed to BioBlue Technologies, Inc. The new name will more accurately reflect the Company’s status as “A Life Sciences Company” involved with both “bio” and “blue” technologies. An amendment to the Company’s Articles of Incorporation to effect the name change was filed with the Florida Department of State on August 4, 2017, but will not be effective with the capital markets until the approval of FINRA has been received. The current name and branding of BioStem Technologies will be retained for our Regenerative Medicine division.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. (OTC PINK: BSEM) is a global life sciences corporation focused on providing world-class technologies with a concentration in Pharmaceuticals, Wellness, Regenerative Medicine and Blue Technologies. We continuously incorporate and innovate through the inclusion of complementary companies and a diversified technology portfolio. This improves the Quality of Life of our consumers and as a result, maximizes shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” believe” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.